Welcome to our dedicated page for Vogenx news (Ticker: VOGX), a resource for investors and traders seeking the latest updates and insights on Vogenx stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vogenx's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vogenx's position in the market.
Vogenx (VOGX) has appointed industry executive Ken Toombs to its Board of Directors and Audit Committee Chair, effective September 21, 2026.
Toombs brings three decades of global professional services experience, including senior leadership roles at PA Consulting, Infosys Consulting, Capgemini Consulting, PricewaterhouseCoopers and IBM, with a background spanning healthcare and life sciences. Vogenx is a clinical-stage biopharmaceutical company developing mizagliflozin, an investigational first-in-class SGLT1 inhibitor, for post-bariatric hypoglycemia (PBH), gastroparesis and GIP-dependent Cushing's Syndrome. Mizagliflozin has been tested in more than 500 subjects across 10 clinical studies and has shown statistically significant effects on postprandial glucose absorption, GIP and insulin secretion, as well as improvements in PBH-related hypoglycemia measures.
Vogenx (NASDAQ: VOGX), a clinical-stage biopharmaceutical company targeting diseases linked to metabolic dysfunction, completed an initial public offering of $81.3 million. The IPO comprised 6,250,000 shares of common stock at $13.00 per share, the high end of the proposed range, with all shares sold by Vogenx.
Gross proceeds to Vogenx were approximately $81.3 million before underwriting discounts, commissions, and expenses. Vogenx shares began trading on the Nasdaq Capital Market under the ticker “VOGX” on August 12, 2026, and the offering closed on August 13, 2026. JonesTrading served as sole book-running manager.
Vogenx (NASDAQ:VOGX), a clinical-stage biopharmaceutical company targeting metabolic disorders such as post-bariatric hypoglycemia (PBH) and gastroparesis, closed its initial public offering of 6,250,000 common shares at $13.00 per share, generating gross proceeds of approximately $81.3 million before fees and expenses.
Vogenx’s stock began trading on the Nasdaq Capital Market on August 12, 2026 under the ticker VOGX. The company granted underwriters a 45-day option to buy up to an additional 937,500 shares. Vogenx’s lead candidate mizagliflozin is being developed for PBH, gastroparesis, and GIP-dependent Cushing's Syndrome.
Vogenx (NASDAQ: VOGX), a clinical-stage biopharmaceutical company focused on metabolic diseases such as post-bariatric hypoglycemia (PBH) and gastroparesis, priced its initial public offering of 6,250,000 common shares at $13.00 per share, at the high end of the range, for expected gross proceeds of approximately $81.3 million before fees and expenses.
The common stock is expected to begin trading on the Nasdaq Capital Market on August 12, 2026, under ticker “VOGX”, with closing expected August 13, 2026, subject to customary conditions. Underwriters have a 45-day option to buy up to 937,500 additional shares at the offering price, less discounts and commissions.